El Hamaky et al. designed and synthesized quinazoline‐1,2,3‐triazole hybrids 65 as multitarget EGFR, VEGFR‐2, and Topo II inhibitors tested them anticancer activity against HeLa, HePG‐2, MCF‐7, and HCT‐116 cancer cell lines. Here, EGFR is linked to cancer.